about
Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus InfectionThe impact of a supervised injecting facility on ambulance call-outs in Sydney, Australia.Substitution therapy for amphetamine users.Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users.Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.Correlates of susceptibility to hepatitis B among people who inject drugs in Sydney, AustraliaBroadening discussions of "safe" in hepatitis C prevention: a close-up of swabbing in an analysis of video recordings of injecting practice.Treating Addictions: Harm Reduction in Clinical Care and Prevention.Estimating the size and dynamics of an injecting drug user population and implications for health service coverage: comparison of indirect prevalence estimation methods.Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.Predictors of completion of a hepatitis B vaccination schedule in attendees at a primary health care centre.The Australasian Professional Society on Alcohol and Other Drugs: from a cottage industry to a regional player.Reducing injecting-related injury and diseases in people who inject drugs: Results from a clinician-led brief intervention.Performance and image enhancing drug injectors' access to needle syringe programs: Responding to a public policy dilemma.Development of immunity following financial incentives for hepatitis B vaccination among people who inject drugs: A randomized controlled trial.Surveillance of injecting-related injury and diseases in people who inject drugs attending a targeted primary health care facility in Sydney's Kings Cross.Clearance of hepatitis C virus after newly acquired infection in injection drug users.A cost-effectiveness analysis of modafinil therapy for psychostimulant dependence.Hepatitis B virus among injecting drug users in Sydney, Australia: prevalence, vaccination and knowledge of status.A randomised controlled trial of financial incentives to increase hepatitis B vaccination completion among people who inject drugs in Australia.A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence.Case study: accessible primary health care--a foundation to improve health outcomes for people who inject drugs.Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence.Process and predictors of drug treatment referral and referral uptake at the Sydney Medically Supervised Injecting Centre.Prevalence of production of virus-specific interferon-gamma among seronegative hepatitis C-resistant subjects reporting injection drug use.The effects of the market withdrawal of temazepam gel capsules on benzodiazepine injecting in Sydney, Australia.The reliability of sensitive information provided by injecting drug users in a clinical setting: clinician-administered versus audio computer-assisted self-interviewing (ACASI).Some characteristics of early-onset injection drug users prior to and at the time of their first injection.
P50
Q27490862-13EC130F-6F1C-4427-901B-392960DD5A14Q34098189-8C16DBC9-F5AA-4AB1-AD3A-F1B6839F3DADQ34790858-233C8022-EFF7-463C-9C4C-6C20531B5465Q35053344-DEEFFBBF-7EAC-4E69-99B8-AABEC2A9120CQ36079786-0835E094-6B87-410D-AC97-8D4839515B71Q36293130-87F9A449-7500-4C1F-AD4B-84A385B08D4AQ37099256-717EABBD-5539-4DD8-8802-F555971C2126Q38817024-2907A92D-7EE6-4F5B-BEA8-7E204AE98EF1Q39137604-7B23E3CB-AACC-44DC-A242-5A1D29AFF513Q40170398-763CE955-445D-4EE5-A8A3-F6F17FEF16B3Q40230699-F00E096C-C4D3-4C02-8D3A-67EF7CC81714Q40251906-1C5D44CB-C0AB-484C-A571-3710C681F6B9Q40725661-CB5B0335-54FD-4AC3-84E7-FB79C8BD1844Q40789346-62C699F5-0348-4654-BC8D-BADF714F3EF4Q41040298-9CE4C6F2-75BF-4FB8-BC6F-5AD35FD04C5EQ41134853-81D4510D-4810-4D07-9495-F0C4310BFABCQ42987301-EE22532B-7E4D-4837-BC4C-862818A83EFAQ43011086-2BCC0421-5793-403B-B4E8-7FAFFE33E4F4Q43202740-0F6612AF-19C2-48B2-8930-EB02475CA05BQ43419623-EBCF1029-CE4C-4BE1-AD2C-7FE05355DB40Q43517293-67EE92B0-9AAD-40B6-9A78-3082F9B16038Q44181611-8039732C-0327-4D44-B7E9-833AE2B9958CQ44520320-4881F6C9-FFB2-43AF-A7AE-F7049E133807Q44660518-2FD37269-4243-41F0-84A1-B624DDC464C9Q45598388-209AFB7E-FBD7-46AD-8C9C-CB22A4C8956AQ46761344-91432DB5-CCAE-4D14-8736-F6799DF941A2Q47977609-2783A754-5BDF-411F-BDFC-D6ABE7A26880Q48453677-62F08299-6DC1-44FE-9941-0FA7F1569D6A
P50
name
Ingrid van Beek
@ast
Ingrid van Beek
@en
Ingrid van Beek
@es
Ingrid van Beek
@nl
type
label
Ingrid van Beek
@ast
Ingrid van Beek
@en
Ingrid van Beek
@es
Ingrid van Beek
@nl
prefLabel
Ingrid van Beek
@ast
Ingrid van Beek
@en
Ingrid van Beek
@es
Ingrid van Beek
@nl